Extended Data Fig. 9: Expansion dynamics of TCR clones that significantly expanded from baseline to on therapy in a partial responder in the SBRT cohort harboring a tumor with low TMB and null PD-L1 expression. | Nature Cancer

Extended Data Fig. 9: Expansion dynamics of TCR clones that significantly expanded from baseline to on therapy in a partial responder in the SBRT cohort harboring a tumor with low TMB and null PD-L1 expression.

From: Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer

Extended Data Fig. 9

Patient 727 had 6 new clones with significant baseline-to-on-therapy expansion in tumor, 19 new clones expanded in blood, and 2 new clones expanded in both compartments. This patient’s TMB and PD-L1 statuses suggest they likely would not respond to ICI monotherapy. Thus, patient 727, who achieved partial response in the SBRT cohort, may represent a group of patients who could benefit most from SBRT-pembrolizumab dual therapy.

Source data

Back to article page